34 results about "Timolol" patented technology

This invention refers to a matter composition of the type used in the treatment of ophthalmic ailments and specifically refers to an ophthalmic carrier solution based on surface-active, emulsifying, antibacterial, antioxidant, etc. Agents which form a carrier that enwraps or masks an active ingredient such as sodium dyclophenac or other antibiotic agents such as tobracin, gentamicin or timolol sulfate, with the aim of avoiding the problems caused by the topical application of the mentioned active ingredients, such as pain, a burning sensation, irritation and other annoyances for the user.

Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

The invention relates to a timolol long-acting transdermal preparation, comprising the following preparation processes: firstly preparing timolol into a timolol nano-drug or timolol micro-powder, and then preparing the timolol nano-drug or timolol micro-powder into a timolol hydrogel transdermal preparation, an ointment transdermal preparation or a micro-needle transdermal preparation. The invention also relates to an application of the drug in hemangioma treatment. When used for treating infantile hemangioma, the medicine disclosed by the invention is capable of improving the medicine absorption efficiency of the pathological cells, and therefore the treatment effect is improved, the dosage is lowered, and no adverse reactions are generated in the treatment process.

The invention relates to the technical field of pharmaceutical preparation, and particularly discloses a timolol liposome and a method for preparing the same. The timolol liposome comprises timolol, phospholipid, cholesterol, antioxidant and the like, wherein the weight percentages of various composition are as follows: 0.01 to 60.00 percent of the timolol, 10.00 to 99.99 percent of the phospholipid, 0.00 to 68.00 percent of the cholesterol, 0.00 to 50.00 percent of the antioxidant, and 0.00 to 89.99 percent of osmotic pressure regulator. A gel matrix can be further added into the timolol liposome to prepare a gel. The timolol liposome has the advantages of high envelop rate, good stability, and excellent biocompatibility, bio-adhesion property and biodegradability, can form very good storage effect in a cornea, and can realize the aims of improving bioavailability, reduce toxicity, and reduce pungency, thus the timolol liposome is particularly suitable for eye instillation to better play the effect of the timolol to reduce the intraocular pressure and resist glaucoma.

Provided herein are methods and compositions for treating gastrointestinal disorders using beta blockers. Compositions comprising Beta blockers such as Timolol and Nadolol are used to treat diseases including ulcerative colitis, IBD and Crohn's disease. The Compositions are administered orally or rectally, at doses that provide a peak plasma concentration of less than 10 ng / ml.

The invention relates to a preparation method of an ointment for treating infantile hemangioma. The preparation method comprises the following steps: adding timolol hydrogenmaleate, propranolole hydrochloride, tacrolimus, pingyangmycin, vitamin C, vitamin E and vitamin B12 to water according to certain mass ratio, heating to 30-85 DEG C of the temperature, adding a thickener, imiquimod and a wetting agent according to certain mass ratio after stirring and dissolving, and uniformly stirring, and preparing the ointment for treating the infantile hemangioma after cooling. The ointment for treating the infantile hemangioma is an external used medicine, particularly suitable for the infants inconvenient for taking medicines and injection.

The invention relates to a pharmaceutical composition for external use. The pharmaceutical composition is characterized by simultaneously containing timolol and allantoin, wherein, timolol can be a free alkali form, and also can be an any pharmaceutically acceptable salt form. The composition preparation has good stability and permeability, and has obvious curative effect for infantile hemangioma.

The invention relates to an ophthalmic gel and a preparation method thereof, in particular to the ophthalmic gel. The ophthalmic gel comprises effective quantity of latanoprost and timolol or salts thereof for treatment and / or prevention, a gel matrix, a surfactant and water. The invention also comprises the ophthalmic gel, an ophthalmic preparation of a medicinal excipient mixed with the ophthalmic gel before being used, and the preparation method of the ophthalmic gel. The ophthalmic gel has the favorable effects of treating eye diseases, and has less adverse effects on a cardiovascular system and a respiratory system of the whole body.

The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.

The invention provides a maleic acid timolol preparation for treating infant superficial hemangioma and application of the maleic acid timolol preparation. The maleic acid timolol preparation adopts water as a dispersing medium and comprises the following components by mass percent with the total percent of 100%: 0.1-1% of maleic acid timolol and 0.5-2% of hyaluronic acid or hyaluronate. The maleic acid timolol preparation provided by the invention is relatively good in viscosity and convenient for medical operators to rub on patients, a film can be formed on the skin surface, the adhesion time is greatly prolonged, and active components can play roles continuously; the maleic acid timolol preparation has a moisturizing function and is not dried within a short time, so that the skin surface can be kept in a wet state for a long time; as the keratoderma of an infant is thin and the water content is higher than that of an adult, the moisturizing function is particularly important for infant skin, however, hyaluronic acid or hyaluronate is not used in infant preparation dressing yet at present; in addition, application of hyaluronic acid or hyaluronate to the dressing shows by accident that the function of promoting wound healing of infant skin can be achieved.

The invention relates to a timolol long-acting transdermal preparation, the preparation process of which comprises: first preparing timolol into timolol nano-medicine or timolol micropowder, and then preparing timolol nano-medicine Or timolol micropowder is prepared into timolol hydrogel transdermal preparation, ointment transdermal preparation or microneedle transdermal preparation. The present invention also relates to the application of the above-mentioned medicine in the treatment of hemangioma. Using the medicine of the invention to treat infantile hemangioma can promote the efficiency of diseased cells to absorb medicine, improve the treatment effect, reduce the dosage of medicine, and have no adverse reaction in the treatment process.

The invention provides timolol hydrogenmaleate gel and a preparation method thereof. The content of the timolol hydrogenmaleate gel is 95.0 to 105.0 percent of the labeled amount, and the timolol hydrogenmaleate gel is transparent or semi-transparent hydrogel and has the pH value between 6.0 and 8.0. The timolol hydrogenmaleate gel disclosed by the invention is high in stability and non-stimulating to the skin and can achieve the medicinal effect through the skin.

A novel method for stabilizing timolol concentration in a container containing an aqueous composition comprising timolol is disclosed. The container is made of a pharmaceutically acceptable, moisture-permeable material. This method comprises the step of enclosing the container in a secondary package. The secondary package is made of a pharmaceutically acceptable material having a low permeability to moisture. A medicinal product comprising an aqueous composition comprising timolol is also disclosed. The composition is packaged in a container made of a pharmaceutically acceptable, moisture-permeable material. The container is enclosed in a secondary package, which is made of a pharmaceutically acceptable material having a low permeability to moisture.

Provided herein are methods and compositions for treating gastrointestinal disorders using beta blockers. Compositions comprising Beta blockers such as Timolol and Nadolol are used to treat diseases including ulcerative colitis, IBD and Crohn's disease. The Compositions are administered orally or rectally, at doses that provide a peak plasma concentration of less than 10ng / ml.

The present invention relates to pharmaceutical composition comprising the beta 1(β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.

The present invention provides a process for preparing optically active timolol. The process comprises the following steps. Firstly, reacting 3-hydroxy-4-morpholino-1,2,5-thiadiazole with an optically active epichlorohydrin in the presence of a solvent system, which has a first volume and a catalyst optionally in the presence of a suitable base to obtain an optically active intermediate product. Secondly, treating the optically active intermediate product with a solution, which has a second volume and comprises tert-butylamine to obtain an optically active timolol. The solvent system used in the first step can be an amide solvent, sulfoxide solvent, cyclic hydrocarbon solvent, ketone solvent, or a heterocyclic solvent. The catalyst used in the first step can be an alkali metal hydroxide, alkali metal carbonate, alkali metal hydrogen carbonate, piperidine, pyridine, triethylamine, potassium hydroxide, sodium hydroxide, potassium carbonate, and other heterocyclic bases.

The invention relates to a novel composition containing timolol and essential oil for promoting the growth of eyelashes or eyebrows, cosmetics containing the composition, and application of the composition for promoting the growth of the eyelashes or the eyebrows.

New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality relatedto an increase in intraocular pressure (IOP), a disorder requiring neuro-protection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a micro-particle in vivo, wherein the timolol prodrug containing micro-particle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.

The present invention relates to the use of timolol in treating rosacea, and to pharmaceutical compositions comprising timolol.

The invention relates to an application of timolol or salts thereof to preparation of a medicine for preventing and / or treating plexiform angioma. The timolol or the salts thereof are used for treating plexiform angioma in a local coating manner, any wounds are not generated, the medicine is simple to use, good in treatment tolerance and high in curing rate and plexiform angioma cannot recur afterbeing healed.

The present invention relates to pharmaceutical composition comprising the [beta]1([beta]1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocularhypertension and / or a symptom associated therewith.

The invention provides a transdermal penetration-promoting composition for improving the transdermal absorption effect of timolol. The transdermal penetration-promoting composition is prepared from 65-98wt% of albolene and 2-35wt% of wax substances. The transdermal penetration-promoting composition can achieve the cumulative penetration amount of timolol of about 92.61 micrograms per square centimeter within 8 hours without additionally using other conventional transdermal penetration-promoting agents, the transdermal absorption promoting effect is remarkable, the skin irritation is low, and the safety is higher.